Product Description
CN128 is designed specifically to be an oral chelation agent for iron-overload conditions and to overcome Deferiprone (a current oral chelator)'s myelo-suppression side effect and low pharmacodynamic efficiency (Sourced from: http://zedepharma.com/importantnotice/index.html)
Mechanisms of Action: Iron Chelator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hangzhou Zed Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Iron Overload|Thalassemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20182220 |
CTR20182220 | P1 |
Completed |
Iron Overload|Thalassemia |
2019-05-06 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT03935633 |
D160605-2 | P1 |
Completed |
Thalassemia |
2019-05-06 |
2019-12-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
CTR20171169 |
CTR20171169 | P1 |
Completed |
Thalassemia|Iron Overload |
2018-10-16 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT03673085 |
D160605 | P1 |
Completed |
Thalassemia |
2018-10-16 |
2019-12-22 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date |
|
NCT05355766 |
A160605-202 | P2 |
Completed |
Iron Overload|Thalassemia |
2024-09-23 |
2025-03-18 |
Primary Endpoints |
|
CTR20201051 |
CTR20201051 | P2 |
Completed |
Thalassemia|Iron Overload |
2022-08-18 |
2025-04-29 |
||
NCT04614779 |
A160605 | P2 |
Completed |
Thalassemia|Iron Overload |
2022-08-18 |
2023-11-27 |
Primary Endpoints |
|
CTR20220915 |
CTR20220915 | P2 |
Completed |
Iron Overload|Thalassemia |
None |
2025-08-05 |
Patient Enrollment|Treatments|Trial Status |